Introduction
============

Over the past decades, the therapeutic strategy of radiation in the management of rectal cancer has evolved [@B1]. Preoperative versus postoperative radiotherapy for stage II/III rectal cancer has been well explored [@B2]. A prospective randomized controlled trial conducted by the German Rectal Cancer Study Group (the CAO/ARO/AIO-94 trial) demonstrated that preoperative chemoradiotherapy was associated with a decrease local recurrence and therapeutic toxicity as compared to postoperative chemoradiotherapy [@B3]. Furthermore, the advantage of local control in preoperative group persisted when it comes to 10-year cumulative incidence of local recurrence. It is regret that overall survival benefit was not observed in this study. In an earlier research, preoperative radiotherapy not only reduces rates of local recurrence but also improves survival among patients with resectable rectal cancer [@B4]. Besides that, preoperative radiation may result in tumor regression that increases the likelihood of sphincter preservation [@B5]. However, preoperative radiotherapy may be unnecessary due to exaggerated clinical stage [@B6]. Taking the advantages and disadvantages into account, the NCCN panel recommends preoperative chemoradiotherapy as a standard treatment for patients with stage II/III rectal cancer.

Due to the lack of randomized data for metastatic rectal resulted from complexity of stage IV disease, the therapeutic decisions are largely extrapolated from stage III rectal cancer. Postoperative adjuvant chemoradiotherapy is recommended for stage IV patients without receiving preoperative chemoradiotherapy or with a high risk for local recurrence after resection of primary lesion. However, the optimal sequencing of radiotherapy in metastatic rectal cancer remains unclear. To fill this gap in present guideline, we retrospectively analyzed data from Surveillance, Epidemiology, and End Results (SEER) database using propensity score matching analyses to determine if there are any survival benefits in patients with metastatic rectal cancer who were received neoadjuvant radiotherapy vs adjuvant radiotherapy.

Material and methods
====================

Data collection
---------------

Patients with metastatic rectal cancer who underwent the resection of primary site and received preoperative and postoperative radiotherapy were identified in the SEER database (2004-2014). This study was approved by the Institutional Review Board of Fudan University Shanghai Cancer Center. The inclusion criteria were listed as follows: The site code represented "rectum (130)"; patients with distant metastases (M1); surgery was performed in primary site; patients with a known treatment sequence consisting of \'\'radiation before surgery\'\' (preoperative radiotherapy), \'\'radiation after surgery\'\' (postoperative radiotherapy); CRC was the only type of primary cancer; information about cancer-specific survival (CSS) and survival months were available.

The following data were collected: age at diagnosis, gender, marital status, race, serum CEA level, histologic type, differentiation status, tumor size, T stage, N stage, CSS, surgery of the metastases, radiation sequence with surgery. CSS was defined as the time from the date of diagnosis to the date of death caused by CRC. To minimize the inherent selection bias in a retrospective background, propensity score matching (PSM) at a 1:1 ratio was performed to compare CSS. The PSM model was based upon age, gender, marital status, race, serum CEA level, histologic type, differentiation status, tumor size, T stage, N stage and surgery of the metastases. The details of PSM process are demonstrated as Figure [1](#F1){ref-type="fig"}.

Statistical analysis
--------------------

The differences between two groups were calculated by using χ2 test. The Kaplan-Meier method was used to analyze CSS and relative 5-year survival rate was calculated. The difference was compared using the log-rank test. Multivariate analyses were performed to recognize the specific factors which influence CSS. All statistical analyses were performed with SPSS 25.0 and R (version 3.4.4).

Results
=======

Characteristics of patients
---------------------------

A total of 2233 metastatic rectal cancer patients who underwent the resection of primary site and received radiotherapy with explicit treatment sequence were identified. After PSM, 686 matched pairs were recruited for comparison of preoperative versus postoperative radiotherapy. The clinicopathological characteristics of patients are comparable between the two groups and summarized in Table [1](#T1){ref-type="table"}. Patients with elevated serum CEA level constituted a higher percentage in preoperative radiotherapy group than in the postoperative radiotherapy group. In terms of other variables, the percentage of patients was similar in two groups.

Survival outcomes
-----------------

Median CSS for patients with preoperative and postoperative radiotherapy was 39 and 32 months, respectively. The Kaplan-Meier survival curves revealed a significant CSS advantage for preoperative radiotherapy (p\<0.001 for log-rank test) (Figure [2](#F2){ref-type="fig"}A). The 5-year CSS estimates were 33.4% (95% CI: 28.9%-37.9%) and 26.8% (95% CI: 22.7%-30.9%) for patients underwent preoperative radiotherapy followed by resection of primary lesion and postoperative radiotherapy after surgery, respectively. The survival benefits were only observed in patients with adenocarcinoma instead of mucinous adenocarcinoma or signet ring cell carcinoma (Figure [2](#F2){ref-type="fig"}B-[2](#F2){ref-type="fig"}D).

In multivariate analysis, age \>60 year at diagnosis (HR=1.393, 95% CI: 1.211-1.603, P\<0.001) was associated with an increased risk of cancer death while married (HR=0.735, 95% CI: 0.636-0.849, P\<0.001), normal serum CEA level (HR=0626, 95% CI: 0.512-0.746, p=\<0.001), preoperative radiotherapy (HR=0.820, 95% CI: 0.712-0.945, p=0.006), and surgery of metastases (HR=0.606, 95% CI: 0.498-0.736, P\<0.001) resulted in decreased risk of cancer death (Table [2](#T2){ref-type="table"}).

Discussion
==========

Neoadjuvant chemoradiotherapy followed by total mesorectal excision has been the standard care for locally-advanced rectal cancer [@B7]. However, the therapeutic algorithm of radiotherapy in metastatic rectal cancer has been little investigated. Similarly, for resectable metastatic cases, the necessity of radiotherapy for local control has not been clarified.

Survival benefits of radiotherapy in metastatic rectal cancer have been shown in several retrospective studies [@B8], [@B9]. However, another study found that postoperative pelvic radiotherapy did not improve recurrence-free survival of metastatic rectal patients after resection of primary tumor [@B10]. Indeed, stage IV rectal cancers comprise a heterogeneous group, which impedes the progress of prospective studies. Several studies with small sample size compared of local recurrence rate and overall survival of stage IV rectal cancer patients with or without neoadjuvant chemoradiotherapy and the results are inconsistent [@B11]-[@B14]. In the present study, we demonstrated that patients with resectable rectal cancer received radiotherapy before definitive primary resection surgery had better prognosis than radiotherapy after surgery using a relative large-population bases database.

Huh et al [@B11] reported the outcomes of 69 patients received chemoradiotherapy and 71 patients did not. They found that preoperative radiotherapy improved local control of metastatic rectal cancer while postoperative radiotherapy did not. Similarly, Fossum et al [@B12] also observed a decreased local recurrence rate for patients who received neoadjuvant radiotherapy compared with those who did not receive radiotherapy. In this study, local recurrence was observed in 26% patients who did not receive radiotherapy, while no local recurrence developed in those who received neoadjuvant radiotherapy. Neoadjuvant radiotherapy demonstrated excellent value for local control in stage IV rectal cancer. However, survival benefit was not observed in the two independent studies. On the contrary, Kim et al [@B13] evaluated the oncological effects of neoadjuvant radiotherapy versus pure postoperative chemotherapy in 86 patients with rectal cancer and synchronous liver metastasis receiving TME procedure and found that neoadjuvant chemoradiotherapy did not improve local control and overall survival. The local recurrence rates were 10% in neoadjuvant chemoradiotherapy group and 15.2% in postoperative systemic chemotherapy without radiotherapy group and did not reach a significant difference. Another retrospective study enrolled 109 patients with metastatic rectal adenocarcinoma who underwent definitive primary resection [@B14]. Compared with patients treated with perioperative chemotherapy alone, no differences were found in terms of local recurrence or overall survival in those who received preoperative radiotherapy. Taken together, the potential advantages of preoperative radiotherapy are hard to determine decisively from these studies. Obviously, a limitation hidden in the above studies is small sample size. Our study eliminates the limitation by analyzing a large-population based database and provides the convincing evidence for the significance of neoadjuvant radiotherapy in resectable metastatic rectal cancer. Further well-designed prospective study should be initiated to explore the optimal therapeutic strategy for these patients and determine which subgroups will benefit the most from this protocol.

It is well documented that distant disease may have a decisive role in prognosis. The resection of distant lesion has been added in our PSM model to reduce the selection bias. Our present study also demonstrated that metastatectomy were significant prognostic factors for CSS in metastatic rectal cancer. In stage IV colorectal cancer, the value of surgery has been well established [@B15], [@B16]. Lin et al [@B17] reported that concurrent chemoradiotherapy followed by resection of metastases converts to survival benefit in metastatic rectal cancer. These results indicated that neoadjuvant chemoradiotherapy and metastatectomy should be taken into consideration for curative intent.

However, there are several inevitable limitations in our present study. The main deficiency is that the data of systemic chemotherapy is unavailable. Although chemotherapy has a critical effect on prognosis of metastatic rectal cancer patients, the chemotherapy regiments and course of treatment are missing in SEER database. Similarly, neither of BMI nor inflammation index which may affect the prognosis are available. Further, despite we employed the propensity score to minimize selection bias, some unknown confounders remain unnoticeable due to its retrospective nature. Moreover, because preoperative radiotherapy may result in tumor down-sizing and down-staging, inclusion of tumor size, T stage and N stage in the PSM model underestimated treatment effect in the preoperative radiotherapy group. A higher percentage of patients with elevated serum CEA level in preoperative radiotherapy group enhanced this effect further.

Despite the above limitations, the relative large sample size, minimal selection bias and sufficient follow-up provide valuable evidence to optimize the therapeutic protocols for resectable metastatic rectal cancer.

In conclusion, for stage IV rectal adenocarcinoma cancer patients received definitive primary resection surgery, we recommend consideration of neoadjuvant radiotherapy instead of postoperative radiotherapy.
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###### 

Clinical characteristics of patients with metastatic patients receiving preoperative or postoperative radiotherapy.

  Variable                     Radiation prior to rectal surgery   Radiation after rectal surgery   P value          
  ---------------------------- ----------------------------------- -------------------------------- --------- ------ -----------
  **Age**                                                                                                            0.550
  ≤60                          387                                 50.7                             376       49.3   
  \>60                         299                                 49.1                             310       50.9   
  **Sex**                                                                                                            0.869
  Male                         406                                 50.2                             403       49.8   
  Female                       280                                 49.7                             283       50.3   
  **Marital status**                                                                                                 0.219
  Unmarried                    252                                 48.3                             270       51.7   
  Married                      421                                 51.7                             393       48.3   
  Unknown                      13                                  36.1                             23        63.9   
  **Race**                                                                                                           0.389
  White                        560                                 50.5                             548       49.5   
  Black                        59                                  44.4                             74        55.6   
  Others                       67                                  51.1                             64        48.9   
  **Serum CEA**                                                                                                      **0.024**
  Elevated                     336                                 57.0                             353       43.0   
  Normal                       146                                 48.8                             110       51.2   
  Unknown                      204                                 47.8                             223       52.2   
  **Histologic type**                                                                                                0.920
  Adenocarcinoma               515                                 50.2                             511       49.8   
  Mucinous adenocarcinoma      71                                  50.0                             71        50.0   
  Signet ring cell carcinoma   8                                   42.1                             11        57.9   
  Others                       92                                  49.7                             93        50.3   
  **Differentiation**                                                                                                0.082
  Well                         29                                  49.2                             30        50.8   
  Moderate                     442                                 52.2                             405       47.8   
  Poor and undifferentiated    154                                 45.0                             188       55.0   
  Unknown                      61                                  49.2                             63        50.8   
  **Tumor size**                                                                                                     0.366
  \<5cm                        256                                 50.7                             249       49.3   
  ≥5cm                         280                                 47.9                             304       52.1   
  Unknown                      150                                 53.0                             133       47.0   
  **T stage**                                                                                                        0.055
  T1+T2                        56                                  42.7                             75        57.3   
  T3+T4                        601                                 51.6                             564       48.4   
  Unknown                      29                                  38.2                             47        61.8   
  **N stage**                                                                                                        
  N0                           125                                 46.0                             147       54.0   0.089
  N+                           533                                 51.7                             497       48.3   
  Unknown                      28                                  40.0                             42        60.0   
  **Surgery of metastases**                                                                                          0.280
  No                           543                                 49.3                             558       50.7   
  Yes                          141                                 53.0                             125       47.0   
  Unknown                      2                                   40.0                             3         60.0   

###### 

Univariate and multivariate analysis for cancer-specific survival in metastatic rectal cancer with resection of primary site.

  Variable                     Univariate analysis   Multivariate analysis                         
  ---------------------------- --------------------- ----------------------- --------------------- -------------
  **Age**                                            **\<0.001**                                   
  ≤60                          34.2                                          Reference             
  \>60                         25.1                                          1.393 (1.211-1.603)   **\<0.001**
  **Sex**                                            0.600                   NI                    
  Male                         31.3                                                                
  Female                       28.5                                                                
  **Marital status**                                 **\<0.001**                                   
  Unmarried                    22.9                                          Reference             
  Married                      34.6                                          0.735 (0.636-0.849)   **\<0.001**
  Unknown                      /                                             /                     
  **Race**                                           0.259                   NI                    
  White                        29.0                                                                
  Black                        35.7                                                                
  Others                       /                                                                   
  **Serum CEA**                                      **\<0.001**                                   
  Elevated                     22.9                                          Reference             
  Normal                       39.3                                          0.626 (0.512-0.746)   **\<0.001**
  Unknown                      /                                             /                     
  **Histologic type**                                **0.001**               NI                    
  Adenocarcinoma               30.8                                                                
  Mucinous adenocarcinoma      29.5                                                                
  Signet ring cell carcinoma   6.3                                                                 
  Others                       30.4                                                                
  **Differentiation**                                **\<0.001**             Reference             
  Well                         22.8                                          0.855 (0.611-1.197)   0.362
  Moderate                     32.8                                          1.397 (0.984-1.984)   0.061
  Poor and undifferentiated    21.4                                          0.956 (0.638-1.433)   0.827
  Unknown                      /                                             /                     
  **Tumor size**                                     0.954                   NI                    
  \<5cm                        31.1                                                                
  ≥5cm                         32.0                                                                
  Unknown                      /                                                                   
  **T stage**                                        0.955                   NI                    
  T1+T2                        34.7                                                                
  T3+T4                        29.6                                                                
  Unknown                      /                                                                   
  **N stage**                                        0.877                   NI                    
  N0                           34.9                                                                
  N+                           29.8                                                                
  Unknown                      /                                                                   
  **Surgery of metastases**                          **\<0.001**                                   
  No                           28.6                                          Reference             
  Yes                          36.3                                          0.606 (0.498-0.736)   **\<0.001**
  Unknown                      /                                             /                     
  **Radiation sequence**                             **\<0.001**                                   
  After surgery                26.8                                          Reference             
  Before surgery               33.3                                          0.820 (0.712-0.945)   **0.006**

NI: not included in multivariate survival analysis.
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